Cipla
Cipla Limited (stylized as Cipla) is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India.
Trade name | Cipla |
|---|---|
| Formerly | Chemical Industrial & Pharmaceutical Laboratories Ltd. (1935–1984) |
| Company type | Public |
Traded as | BSE: 500087 NSE: CIPLA NSE NIFTY 50 Constituent |
| ISIN | INE059A01026 |
| Industry | Pharmaceuticals |
| Founded | 1935 |
| Founder | Khwaja Abdul Hamied |
| Headquarters | Mumbai, Maharashtra, India |
Area served | Worldwide |
Key people |
|
| Products | Pharmaceuticals and diagnostics |
| Revenue | ₹22,753 crore (US$2.8 billion) (FY23) |
| ₹5,027 crore (US$630 million) (FY23) | |
Net income | ₹2,802 crore (US$350 million) (FY23) |
| Total assets | ₹23,662.56 crore (US$3.0 billion) (2020) |
| Total equity | ₹15,763.00 crore (US$2.0 billion) (2020) |
Number of employees | 22,036 |
| Subsidiaries | Invagen Pharmaceuticals |
| Website | www.cipla.com |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.